Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Go back to Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 28.99 -0.37 (1.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.36 | 52 Week High | $5.17 | |||
| Open | $29.57 | 52 Week Low | $0.94 | |||
| Day High | $29.68 | P/E | N/A | |||
| Day Low | $28.40 | EPS | $0.00 | |||
| Volume | 2,670,785 | |||||
